Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 7/20 | 0.98 |
| ▸ | GRIA2 | P42262 | 7/20 | 0.98 |
| ▸ | GRIA3 | P42263 | 7/20 | 0.98 |
| ▸ | GRIA4 | P48058 | 7/20 | 0.98 |
| ▸ | MAPT | P10636 | 4/20 | 0.98 |
| ▸ | HPGD | P15428 | 3/20 | 0.98 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.98 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.98 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.98 |
| ▸ | GRIK4 | Q16099 | 3/20 | 0.98 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | GRM6 | O15303 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | GLA | P06280 | 1/20 | 0.98 |
| ▸ | THRB | P10828 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nbqx SCHEMBL29356960 | 0.99 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| Nbqx SCHEMBL120375 | 0.99 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| Nbqx SCHEMBL3681836 | 0.98 | GRIA1 (0.98) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3678511 | 0.89 | GRIA1 (0.82) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL30389920 | 0.87 | GRIA1 (0.78) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3682827 | 0.85 | GRIA1 (0.75) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3670356 | 0.83 | GRIA1 (0.72) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3683483 | 0.79 | KMT2A (0.67) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3676464 | 0.79 | GRIA1 (0.67) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3691418 | 0.78 | KMT2A (0.65) | GRIA1GRIA2GRIA3GRIA4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110244486-A1 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES | PEREGO, CARLA (IT) | 2011-10-06 | — | — | US | claimed |
| EP-2366106-A2 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES | Perego, Carla (IT) | 2011-09-21 | — | — | EP | claimed |
| WO-2010057647-A2 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2010-05-27 | — | — | WO | claimed |
| EP-1138332-B1 | Treatment of poriomania | AJINOMOTO KK (JP) | 2004-06-09 | — | — | EP | claimed |
| US-12005185-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240076630-A1 | METHODS FOR GENERATING NEURAL TISSUE AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-03-07 | — | — | US | disclosed |
| US-20240065988-A1 | COMBINED USE OF KETAMINE AND RETIGABINE (EZOGABINE) FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-02-29 | — | — | US | disclosed |
| EP-4319731-A1 | A COMBINED USE OF KETAMINE AND RETIGABINE (EZOGABINE) FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Yeda Research and Development Co. Ltd (IL) | 2024-02-14 | — | — | EP | disclosed |
| US-20240002936-A1 | USE OF BRAIN ORGANOIDS AND SINGLE CELL GENOMICS TO UNDERSTAND AND TREAT NEURODEVELOPMENTAL AND NEUROPSYCHIATRIC DISORDERS | THE BROAD INSTITUTE, INC. | 2024-01-04 | — | — | US | disclosed |
| US-20230191047-A1 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20190002835-A1 | METHODS FOR GENERATING NEURAL TISSUE AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2019-01-03 | — | — | US | disclosed |
| US-10093897-B2 | Generation of neuronal cells from pluripotent stem cells | Université Libre de Bruxelles (BE) | 2018-10-09 | — | — | US | disclosed |
| US-20100285113-A1 | ENHANCED STABILITY OF INVERSE THERMAL GELLING COMPOSITE HYDROGELS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2010-11-11 | — | — | US | disclosed |
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100166720-A1 | GENERATION OF NEURONAL CELLS FROM PLURIPOTENT STEM CELLS | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2010-07-01 | — | — | US | disclosed |
| WO-2010057647-A2 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2010-05-27 | — | — | WO | disclosed |
| EP-2028268-A1 | Generation of neuronal cells from pluripotent stem cells | Université Libre De Bruxelles (BE) | 2009-02-25 | — | — | EP | disclosed |
| US-20060148835-A1 | Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-07-06 | — | — | US | disclosed |
| EP-1539149-A2 | MGLU RECEPTORS ANTAGONISTS FOR TREATING DISORDERS ASSOCIATED WITH MGLU RECEPTORS INCLUDING ADDICTION AND DEPRESSION | Novartis AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024150-A2 | MGLU RECEPTORS ANTAGONISTS FOR TREATING DISORDERS ASSOCIATED WITH MGLU RECEPTORS INCLUDING ADDICTION AND DEPRESSION | NOVARTIS AG (CH) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | GRM5, GRM1, GRM3 | GRIA1 10/4885GRIA2 13/4885GRIA3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.